Cite
HARVARD Citation
Gressin, R. et al. (n.d.). FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. Hematological oncology. pp. 141-142. [Online].